Literature DB >> 9641883

Pathology and biology of pancreatic ductal adenocarcinoma.

P Hermanek1.   

Abstract

INTRODUCTION: Ductal adenocarcinoma of the pancreas is a highly aggressive tumor with early local spread beyond the pancreas, predominantly to the retroperitoneum, but also with invasion of adjacent great vessels and adjacent organs. DISCUSSION: Anterior extension may lead to perforation of the visceral peritoneum and spread within the peritoneal cavity. Cytology in peritoneal lavage can be positive before any peritoneal metastasis is seen. Invasion of lymphatics and veins as well as perineural invasion are common. The lymph drainage of the pancreas is multidirectional to superior, inferior, anterior, posterior and left lymph nodes. In node-negative cases, isolated tumor cells in the sinus of regional lymph nodes may be found by immunocytochemistry; such findings must be distinguished from micrometastasis. The same applies to isolated tumor cells in bone marrow. PROGNOSIS: The independent prognostic significance of isolated tumor cells in the regional lymph nodes and in the bone marrow remains to be proven. For classification of anatomic extent the new, fifth edition ( 1997) of the UICC TNM classification should be used. The complex Japanese classification cannot be directly compared with the UICC system.
CONCLUSION: Tumor size and histologic grade influence the extent of spread. Anatomic extent and histologic grade are the strongest predictors of outcome.

Entities:  

Mesh:

Year:  1998        PMID: 9641883     DOI: 10.1007/s004230050102

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  10 in total

1.  Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas.

Authors:  W Meyer; C Jurowich; M Reichel; B Steinhäuser; P H Wünsch; C Gebhardt
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

2.  [Significance of occult lymphatic tumor spread in pancreatic cancer].

Authors:  C Milsmann; L Füzesi; C Werner; H Becker; O Horstmann
Journal:  Chirurg       Date:  2005-11       Impact factor: 0.955

3.  Combining in Vitro Diagnostics with in Vivo Imaging for Earlier Detection of Pancreatic Ductal Adenocarcinoma: Challenges and Solutions.

Authors:  Paul F Laeseke; Ru Chen; R Brooke Jeffrey; Teresa A Brentnall; Jürgen K Willmann
Journal:  Radiology       Date:  2015-12       Impact factor: 11.105

4.  Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma.

Authors:  R Krempien; M W Muenter; W Harms; J Debus
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

5.  Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy.

Authors:  Deyali Chatterjee; Matthew H Katz; Wai Chin Foo; Manonmani Sundar; Hua Wang; Gauri R Varadhachary; Robert A Wolff; Jeffrey E Lee; Anirban Maitra; Jason B Fleming; Asif Rashid; Huamin Wang
Journal:  Am J Surg Pathol       Date:  2017-08       Impact factor: 6.298

6.  Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes.

Authors:  J Däbritz; J Hänfler; R Preston; J Stieler; H Oettle
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

7.  Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas.

Authors:  N B Jamieson; P Glen; D C McMillan; C J McKay; A K Foulis; R Carter; C W Imrie
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

Review 8.  Intraoperative radiation therapy (IORT) in pancreatic cancer.

Authors:  Robert Krempien; Falk Roeder
Journal:  Radiat Oncol       Date:  2017-01-10       Impact factor: 3.481

Review 9.  Differentiating a chronic hyperplastic mass from pancreatic cancer: a challenge remaining in multidetector CT of the pancreas.

Authors:  Daniel T Boll; Elmar M Merkle
Journal:  Eur Radiol       Date:  2003-12       Impact factor: 7.034

10.  Incidence, mechanism and prognostic value of activated AKT in pancreas cancer.

Authors:  M G Schlieman; B N Fahy; R Ramsamooj; L Beckett; R J Bold
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.